The Latest Breaking News on Pharma

The government will negotiate new prices for the commonly prescribed drugs, but the cuts won't take effect until 2026. In the meantime, drugmakers are fighting the negotiations with lawsuits.

Texas joins a handful of states turn to the north for cheaper drugs. But feds have been slow to approve requests, three years after giving initial OK.

Thanks to the non-cyclical nature and the increasing demand for healthcare services, the healthcare industry should continue to brave most market challenges. Hence, it could be an opportune time to explore dominating medical stocks: Elevance Health (ELV), Centene Corp. (CNC), and Molina Healthcare (MOH), which might garner substantial returns for…

The pharma industry is anticipated to stay buoyed in the years to come with consistent medical breakthroughs and rising need to serve an aging population. Therefore, pharma stocks Johnson & Johnson (JNJ), Novartis AG (NVS), and Dr. Reddy's Laboratories (RDY), which possess promising pipelines, could be wise portfolio additions now.…

The pharmaceutical sector appears to be in a favorable position for sustained long-term expansion. While leading pharma stocks Pfizer (PFE) and Teva Pharmaceuticals (TEVA) should benefit from the industry tailwinds, let us analyze which is the better buy for Growth and Value.

Reata Pharmaceuticals stock gained 345% this year through Friday and is a top 2023 stock.

CEOs received average increase of 16% while pay of many working for them failed to keep up with inflation

Businesses relying on the popular but contentious payments model are finding their operations increasingly difficult to stack up, reports Andrew Bevin.

Catalyst Pharmaceuticals (CPRX) reported robust second-quarter results, with its topline reaching an all-time high. Does that mean it's time to buy the pharma stock now? Let’s look at its financial metrics to gauge its prospects….